AZD4017 was originally investigated as a potential treatment for cardiovascular and metabolic disorders, in particular diabetes. Click here to view AZD4017 trials registered with ClinicalTrials.gov.

Mechanism Of Action and Pharmacodynamic Effects

Inhibition of 11β-HSD1 reduces circulating levels of the glucocorticoid, cortisol. Elevated levels of intracellular glucocorticoids are thought to underlie the metabolic syndrome [1] which can progress to type II diabetes [4-5].